This afternoon we watched Merck & drop -1.5% to a price of $98.05 per share. The Large-Cap Pharmaceutical company is now trading -23.83% below its average target price of $128.73. Analysts have set target prices ranging from $100.0 to $155.0 per share for Merck &, and have given the stock an average rating of buy.
Merck &'s short interest — meaning the percentage of the share float that is being shorted — is lower than average at 1.3%. The stock's short ratio is 2.7. At 0.06%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation.
Another number to watch is the company's rate of institutional share ownership, which now stands at 79.4%. In conclusion, we believe there is mixed market sentiment regarding Merck &.
Institutions Invested in Merck &
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Vanguard Group Inc | 10% | 249,803,915 | $24,493,274,628 |
| 2024-09-30 | Blackrock Inc. | 8% | 212,059,737 | $20,792,457,860 |
| 2024-09-30 | State Street Corporation | 5% | 119,026,412 | $11,670,540,059 |
| 2024-09-30 | Wellington Management Group, LLP | 3% | 75,809,383 | $7,433,110,234 |
| 2024-09-30 | Geode Capital Management, LLC | 2% | 59,155,004 | $5,800,148,322 |
| 2024-09-30 | FMR, LLC | 2% | 49,706,304 | $4,873,703,258 |
| 2024-09-30 | Morgan Stanley | 2% | 44,391,822 | $4,352,618,282 |
| 2024-09-30 | Bank of America Corporation | 2% | 38,868,024 | $3,811,009,871 |
| 2024-06-30 | Norges Bank Investment Management | 1% | 33,806,976 | $3,314,774,099 |
| 2024-09-30 | Northern Trust Corporation | 1% | 26,865,365 | $2,634,149,120 |
